Skip to main content
Rua Bioscience Limited logo

Rua Bioscience Limited — Investor Relations & Filings

Ticker · RUA ISIN · NZRUAE0004S1 NZX Manufacturing
Open in API
Filings indexed 231 across all filing types
Latest filing 2026-05-22 Director's Dealing
Country NZ New Zealand
Listing NZX RUA

About Rua Bioscience Limited

https://www.ruabio.com

Rua Bioscience Limited specializes in the research, development, and manufacturing of pharmaceutical-grade medicinal cannabis products. The company focuses on the full value chain of medicinal cannabis, from advanced plant genetics and cultivation to the production of standardized cannabinoid-based medicines. Its product portfolio primarily includes high-quality dried flower and oil formulations designed for clinical applications. Rua Bioscience employs a capital-light business model, prioritizing intellectual property development and strategic partnerships to scale its global reach. The company targets international medicinal markets, with a significant focus on established pharmaceutical distribution channels in Europe and Australasia. By leveraging scientific expertise and sustainable production methods, the company aims to provide consistent, high-potency therapeutic options for patients while maintaining a strong commitment to its social enterprise origins.

Recent filings

Filing Released Lang Actions
Ongoing Disclosure Notice - Paul Naske
Director's Dealing Classification · 95% confidence The document is an ongoing disclosure notice filed under NZX continuous disclosure requirements (Financial Markets Conduct Act 2013), detailing the acquisition of ordinary shares by the CEO (a director/senior manager). It reports a personal share transaction (insider dealing), which clearly falls under “Director’s Dealing” filings.
2026-05-22 English
Capital Change Notice
Share Issue/Capital Change Classification · 88% confidence The document is a formal notice of a capital change by Rua Bioscience Limited, detailing the issuance of 1,400,000 ordinary shares (via options) to the CEO, including share counts, authority, dates, and regulatory listing rules references. It is not a full financial report or earnings release; it specifically announces a share issue/capital change. Therefore, it fits the category “Share Issue/Capital Change.”
2026-05-21 English
Rua Bioscience Market Update
Regulatory Filings Classification · 80% confidence The document is a brief market update for investors, providing commentary on international markets, product opportunities, and company positioning. It does not contain detailed financial statements (so not a report like 10-K or IR), nor is it an earnings release with key metrics (ER). It’s clearly a public release announcement to NZX rather than a substantive investor presentation (IP). It therefore falls into the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-28 English
Expansion into Canada with New Zealand genetics export
Regulatory Filings Classification · 95% confidence The document is a market update announcing Rua Bioscience's expansion into the Canadian market through the export of cannabis genetics. It is a public release dated 13 April 2026 and contains no financial statements, detailed financial data, or regulatory filing references. The content is an announcement of a business development rather than a financial report or regulatory filing. The document length is 2438 characters, which is relatively short and consistent with a press release or market update. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other detailed financial or regulatory document. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2026-04-12 English
Half-Year Financial Results: Significant sales growth
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Half-Year Financial Results' and covers financial performance for the 6 month period ended 31 December 2025. It includes detailed financial data such as revenue, loss before tax, and cash flows, as well as operational commentary and market outlook. The presence of unaudited financial figures and comprehensive discussion of business segments and outlook indicates this is a comprehensive interim financial report. The document length (6118 characters) supports it being a substantive report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2026
2026-02-26 English
Ongoing Disclosure Notice - Anna Stove
Director's Dealing Classification · 100% confidence The document is a disclosure notice regarding the acquisition of shares by a director or senior manager of Rua Bioscience Limited. It references sections of the Financial Markets Conduct Act 2013 and details the number of shares held before and after the transaction, the nature of the transaction (issue of shares), and certification by an authorized person. There is no financial report, earnings data, or management discussion. The document is a regulatory disclosure of insider share transactions by a director, which fits the definition of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a full disclosure of a director's share dealings.
2026-01-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.